FDA tells ADHD drugmakers to warn of risks
Wed, 21 Feb 2007 10:51 PM EST
... WASHINGTON (Reuters) - Companies that make drugs to treat attention deficit hyperactivity disorder must take extra steps to alert patients to possible cardiovascular and psychiatric risks, U.S. health officials said on Wednesday. ...
Related Topics
- ADHD
- Amniocentesis
- Tacrolimus ointment
- Mammography
- Guanfacine
- Carcinogens
- Attention Deficit Hyperactivity (ADHD), Adult
- Attention Deficit Hyperactivity Disorder (ADHD)
- Pimecrolimus Cream 1%
- Dietary Guidelines
- Thalidomide
- Support Groups
- Amantadine
- Food Labeling
- Dopamine
- Medications
- Clonidine
- Biofeedback
- Hyperglycemia
- Drug Safety

Not Signed In -


